MBRX (Moleculin Biotech Inc.) stock: $8.70, $9.1M market cap, $7.3M cash, $1.8M EV, $591.4M fully diluted market cap. Next expected readout: Dec-27. Lead program: Liposomal Annamycin Injection in combination with Cytarabine Injection (Acute Myeloid Leukaemia (AML)), Phase 3. Data from Fully Diluted's biotech stocks database.
What they do
We call this the “MIRACLE” trial (derived from Moleculin R/R AML AnnAraC Clinical Evaluation). A blinded preliminary data readout has been released for the MIRACLE trial, and we expect to have an interim unblinding of data in mid-2026 and an additional unblinding in the second half of 2026, thereby concluding Part A of the two-part trial.
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Status note Pivotal Phase 2B/3 MIRACLE trial (MB-108) in R/R AML. Phase 1B/2 STS lung mets trials completed. Physician-sponsored Phase 1B/2 in 3rd-line pancreatic cancer planned for 2026. FDA Fast Track and Orphan Drug designated for AML and soft tissue sarcoma.
WP1066
Phase 2 · ActiveModality: small molecule
Target p-STAT3
Partnerships Northwestern University (externally funded physician-sponsored trial)
Indications
Glioblastoma (with radiation)(Phase 2)
Status note Externally funded Phase 1B/2 trial of oral formulation in combination with radiation in glioblastoma actively recruiting in adults; pediatric trial in planning. Prior Emory physician-sponsored Phase 1 in pediatric brain tumors concluded Feb 2023.
WP1122
Stage not disclosed · ActiveModality: small molecule
Target glycolysis
Partnerships University of Texas MD Anderson Cancer Center (license)
Indications
not disclosed(Stage not disclosed)
Status note Recommended Phase 2 dose established to potentially enable future externally funded oncology and virology trials; no active trial disclosed.
Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Pipeline
Lead drug
Liposomal Annamycin Injection in combination with Cytarabine Injection
Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.